Cargando…

Early termination in single-parameter model phase II clinical trial designs using decreasingly informative priors

BACKGROUND: To exchange the type of subjective Bayesian prior selection for assumptions more directly related to statistical decision making in clinician studies and trials, the decreasingly informative prior (DIP) is considered. We expand standard Bayesian early termination methods in one-parameter...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chen, Sabo, Roy T., Mukhopadhyay, Nitai D., Perera, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957559/
https://www.ncbi.nlm.nih.gov/pubmed/36846554
http://dx.doi.org/10.18203/2349-3259.ijct20221110
_version_ 1784894854046679040
author Wang, Chen
Sabo, Roy T.
Mukhopadhyay, Nitai D.
Perera, Robert A.
author_facet Wang, Chen
Sabo, Roy T.
Mukhopadhyay, Nitai D.
Perera, Robert A.
author_sort Wang, Chen
collection PubMed
description BACKGROUND: To exchange the type of subjective Bayesian prior selection for assumptions more directly related to statistical decision making in clinician studies and trials, the decreasingly informative prior (DIP) is considered. We expand standard Bayesian early termination methods in one-parameter statistical models for Phase II clinical trials to include decreasingly informative priors (DIP). These priors are designed to reduce the chance of erroneously adapting trials too early by parameterize skepticism in an amount always equal to the unobserved sample size. METHOD: We show how to parameterize these priors based on effective prior sample size and provide examples for common single-parameter models, include Bernoulli, Poisson, and Gaussian distributions. We use a simulation study to search through possible values of total sample sizes and termination thresholds to find the smallest total sample size (N) under admissible designs, which we define as having at least 80% power and no greater than 5% type I error rate. RESULTS: For Bernoulli, Poisson, and Gaussian distributions, the DIP approach requires fewer patients when admissible designs are achieved. In situations where type I error or power are not admissible, the DIP approach yields similar power and better-controlled type I error with comparable or fewer patients than other Bayesian priors by Thall and Simon. CONCLUSIONS: The DIP helps control type I error rates with comparable or fewer patients, especially for those instances when increased type I error rates arise from erroneous termination early in a trial.
format Online
Article
Text
id pubmed-9957559
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-99575592023-02-24 Early termination in single-parameter model phase II clinical trial designs using decreasingly informative priors Wang, Chen Sabo, Roy T. Mukhopadhyay, Nitai D. Perera, Robert A. Int J Clin Trials Article BACKGROUND: To exchange the type of subjective Bayesian prior selection for assumptions more directly related to statistical decision making in clinician studies and trials, the decreasingly informative prior (DIP) is considered. We expand standard Bayesian early termination methods in one-parameter statistical models for Phase II clinical trials to include decreasingly informative priors (DIP). These priors are designed to reduce the chance of erroneously adapting trials too early by parameterize skepticism in an amount always equal to the unobserved sample size. METHOD: We show how to parameterize these priors based on effective prior sample size and provide examples for common single-parameter models, include Bernoulli, Poisson, and Gaussian distributions. We use a simulation study to search through possible values of total sample sizes and termination thresholds to find the smallest total sample size (N) under admissible designs, which we define as having at least 80% power and no greater than 5% type I error rate. RESULTS: For Bernoulli, Poisson, and Gaussian distributions, the DIP approach requires fewer patients when admissible designs are achieved. In situations where type I error or power are not admissible, the DIP approach yields similar power and better-controlled type I error with comparable or fewer patients than other Bayesian priors by Thall and Simon. CONCLUSIONS: The DIP helps control type I error rates with comparable or fewer patients, especially for those instances when increased type I error rates arise from erroneous termination early in a trial. 2022 2022-04-25 /pmc/articles/PMC9957559/ /pubmed/36846554 http://dx.doi.org/10.18203/2349-3259.ijct20221110 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Wang, Chen
Sabo, Roy T.
Mukhopadhyay, Nitai D.
Perera, Robert A.
Early termination in single-parameter model phase II clinical trial designs using decreasingly informative priors
title Early termination in single-parameter model phase II clinical trial designs using decreasingly informative priors
title_full Early termination in single-parameter model phase II clinical trial designs using decreasingly informative priors
title_fullStr Early termination in single-parameter model phase II clinical trial designs using decreasingly informative priors
title_full_unstemmed Early termination in single-parameter model phase II clinical trial designs using decreasingly informative priors
title_short Early termination in single-parameter model phase II clinical trial designs using decreasingly informative priors
title_sort early termination in single-parameter model phase ii clinical trial designs using decreasingly informative priors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9957559/
https://www.ncbi.nlm.nih.gov/pubmed/36846554
http://dx.doi.org/10.18203/2349-3259.ijct20221110
work_keys_str_mv AT wangchen earlyterminationinsingleparametermodelphaseiiclinicaltrialdesignsusingdecreasinglyinformativepriors
AT saboroyt earlyterminationinsingleparametermodelphaseiiclinicaltrialdesignsusingdecreasinglyinformativepriors
AT mukhopadhyaynitaid earlyterminationinsingleparametermodelphaseiiclinicaltrialdesignsusingdecreasinglyinformativepriors
AT pereraroberta earlyterminationinsingleparametermodelphaseiiclinicaltrialdesignsusingdecreasinglyinformativepriors